Fulcrum therapeutics provides business update and 2023 outlook

― ftx-6058 granted fast track designation for sickle cell disease (scd) from fda in december 2022 ― ― completed enrollment in 6 mg and 2 mg dose cohorts of the phase 1b trial of ftx-6058 in scd; enrollment ongoing in 12 mg dose cohort ― ― additional ftx-6058 data from 6 mg cohort of ongoing phase 1b trial show clinically relevant hbf increases of up to 9.5% ― ― plan to complete enrollment in phase 3 reach trial of losmapimod in fshd during 2h'23 ― fulcrum announces ceo transition; robert j. gould, ph.d., former president and founding chief executive officer of fulcrum has been appointed as interim ceo as bryan stuart departs to pursue other opportunities ― ― presentation at j.p. morgan healthcare conference on wednesday, january 11, 2023, at 4:30 p.m. pst/7:30 p.m. est ―
FULC Ratings Summary
FULC Quant Ranking